Ferrer Receives FDA Fast Track Designation for FNP-223 in Progressive Supranuclear Palsy (PSP)
Ferrer, a B Corp-certified international pharmaceutical company, has announced that FNP-223, a novel therapy in-licensed from Asceneuron and aimed at slowing the development of progressive supranuclear palsy (PSP), has received Fast Track designation from the US Food & Drug Administration (FDA). FNP-223, a new molecular entity in active development for PSP, is in an ongoing Phase 2 study to evaluate its safety, efficacy, and pharmacokinetics in adult patients with possible or probable PSP-Richardson syndrome (PSP-RS), the most common clinical variant of this neurodegenerative disease1.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617437460/en/
Ferrer's pharmaceutical production plant in Sant Cugat del Vallés, Barcelona, Spain.
'We are thrilled to receive Fast Track designation from the FDA for FNP-223 in the treatment of PSP. Consistent with our purpose of using business to fight for social justice, we are committed to advancing this promising therapy as quickly as possible to benefit as many patients as possible,' said Mario Rovirosa, Chief Executive Officer of Ferrer.
Fast Track designation is a significant milestone in the drug development process. It is a program that offers the possibility of having more frequent meetings with the FDA to discuss the drug's development, eligibility for Accelerated Approval and Priority Review if relevant criteria are met.
'This designation underscores the importance of expediting the development and review of FNP-223 to address critical unmet needs in patients with this rare and devastating disease,' said Marta Parmar, Ferrer's Chief Quality, Regulatory and Pharmacovigilance Officer.
Progressive supranuclear palsy manifests in patients with symptoms such as difficulty speaking, imbalance, changes in gait, cognitive problems2-4. PSP has a prevalence of approximately 5 cases per 100,000 people and primarily affects individuals over the age of 603. The disease's etiology is believed to be related to the abnormal accumulation of tau proteins in certain areas of the brain, leading to neurodegeneration3,4. Preclinical models have demonstrated that FNP-223 can prevent the abnormal accumulation of tau proteins in neurons5. Ferrer now aims to show that this molecule is safe and effective in patients with PSP.
Oscar Pérez, Chief Scientific Officer of Ferrer, also expressed his enthusiasm: 'Receiving Fast Track designation is a significant milestone in our journey to provide a transformative treatment for PSP. We are excited to advance our research and hopefully offer a new therapeutic option earlier for patients living with this challenging condition.'
About FNP-223
FNP-223 is a new orally administered chemical compound that functions as a reversible and substrate-competitive inhibitor of the O-GlcNAcase (OGA) enzyme5. Mechanistically, FNP-223 binds to the active site of OGA enzyme. As a result, the inhibitor prevents the substrate from accessing the catalytic pocket, thereby impeding the removal of O-GlcNAc modifications from natural client proteins such as the tau protein. Inhibiting O-GlcNAcase is expected to cause a rapid increase of O-GlcNAcylated (glycosylated) tau proteins, ultimately leading to a reduction in abnormal aggregated tau as neurofibrillary tangles (NFT) over a certain period5.
Bibliography:
1. ClinicalTrials.gov A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 (Oral Formulation) to Slow the Disease Progression of Progressive Supranuclear Palsy (PSP) (PROSPER). ClinicalTrials.gov [Internet]. Available from: https://www.clinicaltrials.gov/study/NCT06355531 .
2. Coughlin DG, Litvan I. Progressive supranuclear palsy: Advances in diagnosis and management. Parkinsonism Relat Disord. 2020 Apr;73:105-116. doi: 10.1016/j.parkreldis.2020.04.014. Epub 2020 May 25.
3. Agarwal S, Gilbert R. Progressive Supranuclear Palsy. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526098/ .
4. Rowe JB, Holland N, Rittman T. Progressive supranuclear palsy: diagnosis and management. Pract Neurol. 2021;21(5):376-383. doi: 10.1136/practneurol-2020-002794.
5. Permanne B, Sand A, Ousson S, Nény M, Hantson J, Schubert R, et al. D. O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies. ACS Chem Neurosci. 2022 Apr 20;13(8):1296-1314. doi: 10.1021/acschemneuro.2c00057.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250617437460/en/
Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
FDA warning: Don't eat these potentially radioactive shrimp sold at Walmart
You might want to think twice about buying this brand of shrimp next time you're shopping at Walmart. The U.S. Food and Drug Administration issued a warning to consumers about eating, selling or serving select brands of Great Value frozen raw shrimp due to contamination with a radioactive isotope. U.S. Customs and Border Protection alerted the FDA about the radioactive isotope, Cesium-137, after it was found in shipping containers at four U.S. seaports, according to the FDA. Here's what you need to know about the products that are affected and whether a recall will be imminent. What contaminated shrimp is the FDA warning consumers about? The Frozen Raw Ez Peel Tail-On Farm-Raised White Vannamei Shrimp in 2-pound bags distributed by Indonesia's BMS Foods tested positive for the contamination. The FDA is recommending a recall on certain BMS shrimp products even if they did not test positive. While a recall hasn't been conducted yet, the FDA is working with distributors and retailers 'to recommend' a recall. The following products are affected: Great Value brand frozen raw shrimp, lot code: 8005540-1, Best by Date: 3/15/2027 Great Value brand frozen raw shrimp, lot code: 8005538-1, Best by Date: 3/15/2027 Great Value brand frozen raw shrimp, lot code: 8005539-1, Best by Date: 3/15/2027 The products were sold in Walmart stores in Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia, according to the FDA. What should people do if they have the contaminated raw shrimp? The FDA is advising people who might have raw, frozen shrimp in their freezers from Walmart that matches the descriptions to not cook or consume them. Instead, the agency is asking customers, distributors and retailers to throw the shrimp away. The FDA also says, 'If you suspect you have been exposed to elevated levels of cesium, talk to your healthcare provider.' Consuming food or water contaminated with Cs-137 in low doses over an extended period of time can create an elevated risk of cancer due to a breakdown in DNA in the body's living cells, according to the FDA. Our journalism needs your support. Please subscribe today to Katherine Rodriguez can be reached at krodriguez@ Have a tip? Tell us at Solve the daily Crossword
Yahoo
an hour ago
- Yahoo
FDA Pushes Back Eylea HD Review; Regeneron Still Gains
This article first appeared on GuruFocus. Regeneron (NASDAQ:REGN) picked up gains Tuesday after announcing that the FDA pushed back decision timelines for two key reviews of its high-dose Eylea (aflibercept) injection. The new action dates fall in the fourth quarter of 2025, covering a prior-approval supplement for a prefilled syringe and a label expansion filing to treat macular edema after retinal vein occlusion (RVO). Warning! GuruFocus has detected 3 Warning Signs with REGN. The company is also seeking to expand Eylea HD's dosing schedule to every 4 weeks across approved uses a shift from the current 816 week regimen for patients with wet AMD and diabetic macular edema. The extension stems from additional information submitted after an FDA inspection at Catalent Indiana LLC, the third-party manufacturer recently acquired by Novo Nordisk (NVO). The FDA classified the new submission as a major amendment, automatically extending review timelines. Novo Nordisk provided a detailed response earlier this month in an effort to address the agency's concerns. For now, Eylea HD remains available via vial administration, but the delay tempers near-term expectations around label expansion and convenience upgrades. Still, investors seem encouraged, with shares moving higher on confidence the regulator will complete its review later this year. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
The Hill
an hour ago
- The Hill
Walmart recalls frozen shrimp over potential radioactive contamination
Walmart has recalled frozen, raw shrimp sold in 13 states because federal health officials say it could have potential radioactive contamination. The U.S. Food and Drug Administration asked Walmart to pull three lots of Great Value brand frozen shrimp from stores after federal officials detected Cesium-137, a radioactive isotope, in shipping containers and a sample of breaded shrimp imported from Indonesia. The products could pose a 'potential health concern' for people exposed to low levels of Cesium-137 over time, FDA officials said. 'If you have recently purchased raw frozen shrimp from Walmart that matches this description, throw it away,' FDA officials said in a statement. The risk from the recalled shrimp is 'quite low,' said Donald Schaffner, a food safety expert at Rutgers University. Cesium-137 is a byproduct of nuclear reactions, including nuclear bombs, testing, reactor operations and accidents. It's widespread around the world, with trace amounts found in the environment, including soil, food and air. The level detected in the frozen breaded shrimp was far lower than FDA intervention levels. However, the agency said that avoiding potentially contaminated products could reduce exposure to low-level radiation that could lead to health problems over time. The FDA is investigating reports of Cesium-137 contamination in shipping containers and products processed by P.T. Bahari Makmur Sejati, doing business as BMS Foods of Indonesia. U.S. Customs and Border Protection officials alerted FDA that they found Cesium-137 in shipping containers sent to U.S. ports in Los Angeles, Houston, Miami and Savannah, Georgia. FDA officials collected several product samples and detected contamination in one sample of frozen breaded shrimp. The shipping containers and products were denied entry into the U.S. However, the FDA then learned that Walmart had received potentially affected products imported after the first detection, from shipments that did not trigger contamination alerts. Walmart immediately recalled the products, a company spokesperson said. They include Great Value brand frozen raw shrimp with lot codes 8005540-1, 8005538-1 and 8005539-1, all with best-by dates of March 15, 2027. The shrimp was sold in Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia. Consumers should discard the products or return them to any Walmart store for refund. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
